Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.
Jason GrebelyPhillip ReadEvan B CunninghamMartin WeltmanGail V MatthewsAdrian DunlopMark MontebelloMarianne MartinelloRosie GilliverPhilippa MarksTanya L ApplegateGregory J Dorenull nullPublished in: Health science reports (2020)
Elbasvir/grazoprevir is effective among people with HCV G1 with recent injecting drug use. Implementation of point-of-care HCV RNA testing was feasible, but the high error rate requires investigation.